Impact Factor
3.88
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.92
1,956 total citations
h5-index
49
h5 depth signal
Cited share
77.2%
402 of 521
Total citations
1,956
Citation footprint
Metric signal
4.00
External metric anchor
Self-citation
3.3%
65 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,351
China
122
Italy
117
United Kingdom
116
Canada
114
Citing Fields of Research
Oncology
968
Lung Cancer
640
Genetics & Genomics
338
Breast Cancer
246
Liver & Colon Cancer
240
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,125
Articles tracked across the journal lifetime
Indexed publication set
521
402 cited publications
Last 12 months
315
26.3 publications/month
Open access share
34.3%
108 OA publications in the last year
Leading citing country
United States
1,351 citing publications
Leading citing field
Oncology
968 citing publications
Latest tracked publication
1 October 2026
10 recent records available
Coverage & Indexing History
v5, 2021-
v5, 2021- ; Selected citations only before this date
Research Focus & Classification
Indexed Subjects
Oncology
Lung Cancer
Liver & Colon Cancer
Breast Cancer
Genetics & Genomics
Issuing & Sponsoring Bodies
publisher
American Society of Clinical Oncology
Broad Categories
Neoplasms
Lung Cancer
Genetics & Genomics
Digestive Disorders
Prostate Cancer
Urology
Liver & Colon Cancer
MeSH Descriptors
Molecular Targeted Therapy
Neoplasms
Pharmacogenetics
Precision Medicine
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1200/po-26-00703
Open DOI
Cobimetinib + Vemurafenib in Patients With BRAF V600E–Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study
Purpose: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with advanced thyroid (TC)...
02
DOI 10.1200/po-26-00484
Open DOI
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study
Purpose: Immunotherapy with chemotherapy significantly improves progression-free survival in advanced endometrial cancer (EC), especially in microsatellite instability-high (MSI-H) cases. Despite this, for recurrent EC in the postimmunot...
03
DOI 10.1200/po-26-00390
Open DOI
Plasma-Derived Genomic Instability Status and Rucaparib Outcomes in Metastatic Castration-Resistant Prostate Cancer: TRITON2
Purpose: BRCA1/2 mutation testing identifies patients with metastatic castration-resistant prostate cancer (mCRPC) eligible for poly(ADP-ribose) polymerase inhibitors; however, clinical outcomes remain heterogeneous within these genotype...
04
05
DOI 10.1200/po-26-00691
Open DOI
Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab
PURPOSE: Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor D...
06
DOI 10.1200/po-26-00363
Open DOI
Patient-Derived Organoids and the Next Phase of Functional Precision Oncology
07
DOI 10.1200/po-26-00300
Open DOI
Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas
Purpose: Skin adnexal carcinomas (SACs) are rare and heterogeneous tumors with no established systemic treatment options and poor long-term survival rates in the advanced disease setting. Here, we aimed to characterize the genomic landsc...
08
DOI 10.1200/po-25-01195
Open DOI
Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity With High-Density Progenitor Cell Regions Correlating With High-Risk Disease
Purpose: No curative options are available for medulloblastoma (MB) in the relapse setting. The tumor microenvironment (TME) influences progression and therapy response, presenting a promising target for therapeutic advances. Prior singl...
09
DOI 10.1200/po-26-00454
Open DOI
Sunitinib in Patients With Various Solid Tumors With FGFR1 / 2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
PURPOSE: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with various solid tumors ...
10
DOI 10.1200/po-26-00366
Open DOI
Genomic Analysis Using Liquid Biopsy: Considerations for Pretest Counseling in UK Practice
Modern cancer diagnostics is heavily reliant on molecular data. Next-generation sequencing using liquid biopsy (LB) is primarily focused on identifying predictive and prognostic biomarkers to guide systemic therapy decision making. Howev...
Bibliographical & Catalog Notes
Articles published as received and cumulated in issue for 2017.
Chronological designation from contents page.